mGluR4-positive allosteric modulation as potential treatment for Parkinson's disease.
about
Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs)Measures of anxiety, sensorimotor function, and memory in male and female mGluR4⁻/⁻ mice.Re-exploration of the PHCCC Scaffold: Discovery of Improved Positive Allosteric Modulators of mGluR4Synthesis and SAR of novel, 4-(phenylsulfamoyl)phenylacetamide mGlu4 positive allosteric modulators (PAMs) identified by functional high-throughput screening (HTS).Development of allosteric modulators of GPCRs for treatment of CNS disordersDiscovery, Synthesis, and Preclinical Characterization of N-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4).Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor.Solution-phase parallel synthesis and SAR of homopiperazinyl analogs as positive allosteric modulators of mGlu₄.Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptParkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Metabotropic glutamate receptor 4 in the basal ganglia of parkinsonian monkeys: ultrastructural localization and electrophysiological effects of activation in the striatopallidal complex.Impaired hippocampus-dependent and facilitated striatum-dependent behaviors in mice lacking the δ opioid receptor.Radiosynthesis of N-(4-chloro-3-[(11)C]methoxyphenyl)-2-picolinamide ([(11)C]ML128) as a PET radiotracer for metabotropic glutamate receptor subtype 4 (mGlu4).Synthesis and SAR of a novel positive allosteric modulator (PAM) of the metabotropic glutamate receptor 4 (mGluR4).Metabotropic glutamate receptor 4 (mGlu4)-positive allosteric modulators for the treatment of Parkinson's disease: historical perspective and review of the patent literature.Recent progress on the identification of metabotropic glutamate 4 receptor ligands and their potential utility as CNS therapeutics.Group III metabotropic glutamate receptors: pharmacology, physiology and therapeutic potential.Novel metabotropic glutamate receptor 4 and glutamate receptor 8 therapeutics for the treatment of anxiety.Drug Design Strategies for GPCR Allosteric Modulators.Delta Opioid Receptors: Learning and Motivation.N-Pyrrylarylsulfones with High Therapeutic Potential.Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata.mGlu Receptors and Cancerous Growth.Discovery of 3-aminopicolinamides as metabotropic glutamate receptor subtype 4 (mGlu4) positive allosteric modulator warheads engendering CNS exposure and in vivo efficacy.Discovery and characterization of a novel series of N-phenylsulfonyl-1H-pyrrole picolinamides as positive allosteric modulators of the metabotropic glutamate receptor 4 (mGlu4).Synthesis and SAR of a novel metabotropic glutamate receptor 4 (mGlu4) antagonist: unexpected 'molecular switch' from a closely related mGlu4 positive allosteric modulator.mGluR4 positive allosteric modulators with potential for the treatment of Parkinson's disease: WO09010455.Improved spatial learning is associated with increased hippocampal but not prefrontal long-term potentiation in mGluR4 knockout mice.
P2860
Q24650602-918E34C6-CE71-4D8C-A9BD-8215323F2306Q30455764-62A06DF4-EB65-4E91-909E-1F2D7FDD96F9Q30475109-9DFA16C3-1B63-4199-85C0-21455E6BD980Q34069332-4CCBFEFE-70EA-4005-88E7-77F06595FFAFQ34373958-70394713-BE77-42C8-8F42-3EE6D6C8DC80Q34522043-D17CD669-3282-4914-891C-F20EF5C8DF97Q34545629-CBB19EF9-F31C-4F44-80E4-28D54BC0474FQ34673489-6B7A324E-A1B3-4D2D-B8BA-66A439E5AD00Q35580900-698AB072-7458-4D1D-8F3E-41E7D7407643Q35614156-7622AABC-BB25-4E01-9604-1E5FD927879FQ36374309-AD1FF1C5-C7EE-46F3-9722-EBF56C754C33Q36775271-C7445F2F-1C56-40B0-8C83-1EC27604F214Q37265062-1E590972-1D58-4371-9BFC-E4BDC7BAEB94Q37364758-D3B68846-7841-4675-9DBB-04D6DBF9A8ABQ38002888-0041567C-2999-4DE7-8DB1-257B587ADF0AQ38031832-9A2217A6-7E98-4AF8-BDBA-C991A8B511DEQ38242117-B591BE1F-8336-433E-B0B0-C5BE8123DCB1Q38292149-CAC35BA4-C328-4552-B307-D3CB4A3656BCQ38813916-727E0E2A-3F1D-4B05-8027-FBDD67C1BF8EQ39062836-09600191-D7FF-4C42-9439-839058DA8CD6Q39173240-8F3872C2-988D-42B8-980E-4817C6FCE43EQ39265062-24077C45-8D35-4E61-BE8B-FD671F794A09Q42019418-157BC996-09D3-4DDF-9017-2181F8D6E016Q42145142-A958EBB5-962D-4C9D-8F30-1EE2CAD7CF6EQ42409715-F5B95CFD-82F1-4467-B907-97F5ECED07F3Q42557866-B99382BC-62DC-43FA-A015-3680FA639D16Q43151764-56DB5DFC-129B-4477-81F0-12243AA2E4B8Q50313262-FF327C82-950D-41E6-B2AF-90DC2FE1A309
P2860
mGluR4-positive allosteric modulation as potential treatment for Parkinson's disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
mGluR4-positive allosteric modulation as potential treatment for Parkinson's disease.
@en
mGluR4-positive allosteric modulation as potential treatment for Parkinson's disease.
@nl
type
label
mGluR4-positive allosteric modulation as potential treatment for Parkinson's disease.
@en
mGluR4-positive allosteric modulation as potential treatment for Parkinson's disease.
@nl
prefLabel
mGluR4-positive allosteric modulation as potential treatment for Parkinson's disease.
@en
mGluR4-positive allosteric modulation as potential treatment for Parkinson's disease.
@nl
P2860
P50
P356
P1476
mGluR4-positive allosteric modulation as potential treatment for Parkinson's disease
@en
P2860
P304
P356
10.4155/FMC.09.38
P577
2009-06-01T00:00:00Z